Track CNTX and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Context Therapeutics Inc
2001 Market Street, Philadelphia, PA, United States, 19103
IPO
2021
Employees
15
Industry
Biotechnology
Sector
Healthcare
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20250+3
3
Analyst Ratings
3 analysts covering
Buy100%recommend buy
Buy
3
Hold
0
Sell
0